Skip to main contentSkip to navigationSkip to search


Camurus submits its first UN Global Compact Communication on Progress and renews the Nasdaq Transparency Partner certificate

24 June 2024

Camurus has in June for the first time submitted the annual Communication on Progress questionnaire for the United Nations Global Compact (UNGC), the world's largest sustainability network for companies. The questionnaire focuses on five disclosure areas (governance, human rights, labor, environment and anti-corruption) and is designed to help participating companies monitor performance across the ten principles of UNGC within the areas of human rights, labor law, environment and anti-corruption.

“Reporting our annual Communication on Progress is a key component in our commitment to working to contribute to the UN's Sustainability Development Goals (SDGs) and the ten principles of the UNGC”, says Iris Rehnström, Director Sustainability at Camurus. “Since we became participant in the UNGC last year, we have made significant progress in our sustainability performance, such as further strengthened our compliance framework, implemented vendor sustainability due diligence and risk assessment, reduced our environmental footprint and improved our sustainability reporting within different areas.”

Camurus’ commitment to improving the lives of patients with severe and chronic diseases has a clear sustainability perspective. Key focus of Camurus’ sustainability work is to increase access to the company’s medicines for as many patients as possible, with products being produced and used in a sustainable way. By conducting an ambitious sustainability work throughout the company’s value chain, Camurus contributes to nine out of 17 of the UN SDGs. 

In addition, Camurus in May 2024 renewed the company’s certificate as Nasdaq Transparency Partner, which demonstrates Camurus’ commitment to market transparency and raising environmental standards.

More information about UN Global Compact:
More information about Camurus’ sustainability work, including SDG analysis:
See Nasdaq’s ESG Data Portal website:

About Camurus
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit

TypeError: Cannot read properties of undefined (reading 'url')